Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor-based regimens.
Authors
- J. Alcami
- Anna Cruceta
- Berta Torres (ORCID: https://orcid.org/0000-0003-1996-4726)
- Alberto Foncillas (ORCID: https://orcid.org/0000-0001-9253-3186)
- Jordi Blanch (ORCID: https://orcid.org/0000-0003-2597-8454)
- Jhon Rojas (ORCID: https://orcid.org/0009-0002-4980-263X)
- Jùlia Calvo
- María Mar Mosquera
- José M. Miró
- Abiu Sempere
- Iván Chivite
- Jose L Blanco
- Lorena de la Mora
- Elisa de Lazzari
- Sonsoles Sanchez-Palomino
- Juan Ambrosioni
- Montserrat Laguno
Institutions
- Real Academia Española (ES)
- Instituto de Salud Carlos III (ES)
- Hospital Universitari de Santa Maria (ES)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Althaia (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital de Sant Joan Despí Moisès Broggi (ES)
- Barcelona Institute for Global Health (ES)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1093/jac/dkag040
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00